Clinical vaccination studies using full-length recombinant proteins have the advantage that this form of antigen potentially includes the full range of epitopes for<unk> + and CD8+ T T<unk> . In addition, it is likely that protein vaccination leads to presentation of epitopes in the context of various HLA alleles, and therefore this type of vaccine should be applicable to any patient regardless of HLA restriction. To date, only one clinical study using MAGE-3 protein as a vaccine has been reported. Using a cloning approach, one patient was shown to have a<unk> + T<unk> response to HLA-DR1-restricted peptide 267–282.
Cancer vaccine targeting CD4+ T cells
Dendritic cell-based cancer vaccine
Tumor antigen vaccine
T cell receptor T cell therapy
Individualized cancer immunotherapy
Active immunotherapy
T-cell vaccination
Vaccine therapy